Li Haiyan, Guan Ting, Qin Shi, Xu Qihao, Yin Lina, Hu Qingzhong
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 232 East Waihuan Road, Panyu, Guangzhou, China.
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, 232 East Waihuan Road, Panyu, Guangzhou, China.
Drug Discov Today. 2023 Mar;28(3):103471. doi: 10.1016/j.drudis.2022.103471. Epub 2023 Jan 5.
Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are hepatic manifestations of systemic metabolic dysfunction, which affect one-quarter of the adult population worldwide as estimated, and exhibit high risk in progressing to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Current drug discovery focuses on modifying homeostasis of lipids, carbohydrates, and cholesterol, as well as inhibiting inflammation and fibrogenesis. Many natural products show promising activities on various molecular targets involving these mechanisms; however, they have not been fully exploited. Since some compounds are components of healthy food, they may be employed in chemoprevention as adjuvants to lifestyle modification, while natural products such as alkaloids and sesquiterpenoids could serve as promising starting points for structural modifications and deserve further development.
非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)是全身代谢功能障碍的肝脏表现,据估计,全球四分之一的成年人受其影响,并且进展为肝纤维化、肝硬化和肝细胞癌的风险很高。当前的药物研发集中在调节脂质、碳水化合物和胆固醇的稳态,以及抑制炎症和纤维化形成。许多天然产物在涉及这些机制的各种分子靶点上显示出有前景的活性;然而,它们尚未得到充分利用。由于一些化合物是健康食品的成分,它们可作为生活方式改变的辅助手段用于化学预防,而生物碱和倍半萜类等天然产物可作为有前景的结构修饰起点,值得进一步开发。